

# Joseph W Golden

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7041540/publications.pdf>

Version: 2024-02-01

33  
papers

1,554  
citations

304602

22  
h-index

377752

34  
g-index

35  
all docs

35  
docs citations

35  
times ranked

2429  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Nucleic Acid-Based Orthopoxvirus Vaccine Targeting the Vaccinia Virus L1, A27, B5, and A33 Proteins Protects Rabbits against Lethal Rabbitpox Virus Aerosol Challenge. <i>Journal of Virology</i> , 2022, 96, JVI0150421.	1.5	31
2	Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. <i>MBio</i> , 2022, 13, e0290621.	1.8	17
3	The host inflammatory response contributes to disease severity in Crimean-Congo hemorrhagic fever virus infected mice. <i>PLoS Pathogens</i> , 2022, 18, e1010485.	2.1	12
4	A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. <i>Npj Vaccines</i> , 2021, 6, 31.	2.9	25
5	Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. <i>Journal of General Virology</i> , 2021, 102, .	1.3	6
6	Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. <i>Journal of Virology</i> , 2020, 94, .	1.5	58
7	Human angiotensin-converting enzyme 2 transgenic mice infected with SARS-CoV-2 develop severe and fatal respiratory disease. <i>JCI Insight</i> , 2020, 5, .	2.3	186
8	Animal Models for Crimean-Congo Hemorrhagic Fever Human Disease. <i>Viruses</i> , 2019, 11, 590.	1.5	51
9	GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. <i>Science Advances</i> , 2019, 5, eaaw9535.	4.7	56
10	Persistent Crimean-Congo hemorrhagic fever virus infection in the testes and within granulomas of non-human primates with latent tuberculosis. <i>PLoS Pathogens</i> , 2019, 15, e1008050.	2.1	32
11	[18F]DPA-714 PET Imaging Reveals Global Neuroinflammation in Zika Virus-Infected Mice. <i>Molecular Imaging and Biology</i> , 2018, 20, 275-283.	1.3	21
12	Exploring Crimean-Congo Hemorrhagic Fever Virus-Induced Hepatic Injury Using Antibody-Mediated Type I Interferon Blockade in Mice. <i>Journal of Virology</i> , 2018, 92, .	1.5	41
13	African and Asian Zika Virus Isolates Display Phenotypic Differences Both In Vitro and In Vivo. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 432-444.	0.6	65
14	Human polyclonal antibodies produced in transchromosomal cattle prevent lethal Zika virus infection and testicular atrophy in mice. <i>Antiviral Research</i> , 2017, 146, 164-173.	1.9	22
15	An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection. <i>Scientific Reports</i> , 2017, 7, 4679.	1.6	21
16	Neuropathogenesis of Zika Virus in a Highly Susceptible Immunocompetent Mouse Model after Antibody Blockade of Type I Interferon. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005296.	1.3	103
17	A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005908.	1.3	76
18	Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever. <i>Journal of Virology</i> , 2016, 90, 3515-3529.	1.5	21

#	ARTICLE	IF	CITATIONS
19	Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses. <i>BioMed Research International</i> , 2015, 2015, 1-31.	0.9	42
20	Impact of Host Proteases on Reovirus Infection in the Respiratory Tract. <i>Journal of Virology</i> , 2012, 86, 1238-1243.	1.5	27
21	Side-by-Side Comparison of Gene-Based Smallpox Vaccine with MVA in Nonhuman Primates. <i>PLoS ONE</i> , 2012, 7, e42353.	1.1	36
22	Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease. <i>Virology Journal</i> , 2011, 8, 441.	1.4	23
23	The strategic use of novel smallpox vaccines in the post-eradication world. <i>Expert Review of Vaccines</i> , 2011, 10, 1021-1035.	2.0	18
24	Evaluating the Orthopoxvirus Type I Interferon-Binding Molecule as a Vaccine Target in the Vaccinia Virus Intranasal Murine Challenge Model. <i>Vaccine Journal</i> , 2010, 17, 1656-1665.	3.2	8
25	Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. <i>Vaccine</i> , 2009, 28, 494-511.	1.7	61
26	Heterogeneity in the A33 protein impacts the cross-protective efficacy of a candidate smallpox DNA vaccine. <i>Virology</i> , 2008, 377, 19-29.	1.1	35
27	Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies. <i>Vaccine</i> , 2008, 26, 3507-3515.	1.7	32
28	Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. <i>Vaccine</i> , 2007, 25, 1814-1823.	1.7	153
29	Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein. <i>Virology</i> , 2007, 368, 331-341.	1.1	47
30	Neutrophil elastase, an acid-independent serine protease, facilitates reovirus uncoating and infection in U937 promonocyte cells. <i>Virology Journal</i> , 2005, 2, 48.	1.4	15
31	Cathepsin S Supports Acid-independent Infection by Some Reoviruses. <i>Journal of Biological Chemistry</i> , 2004, 279, 8547-8557.	1.6	47
32	Addition of Exogenous Protease Facilitates Reovirus Infection in Many Restrictive Cells. <i>Journal of Virology</i> , 2002, 76, 7430-7443.	1.5	63
33	Role of Flagella in Host Cell Invasion by <i>Burkholderia cepacia</i> . <i>Infection and Immunity</i> , 2002, 70, 1799-1806.	1.0	101